Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors. The proposed financing adds potential dilution and interest obligations, while the use of proceeds and final conversion terms will determine the setup for HALO.
Halozyme announced on Sept. 16 that it intends to offer $1.05 billion in aggregate principal amount of convertible senior notes due 2033. The transaction remains subject to market conditions and other factors, so the announcement does not establish the final size, pricing, conversion terms or completion of the offering.
The financing follows a 2025 fiscal year in which Halozyme reported revenue of $1.4 billion, up 37.6% year over year, with diluted EPS of $2.56. Against that operating base, the proposed notes represent a sizable new capital-market transaction, but the announcement does not state how the proceeds will be used.
For Halozyme, the direct mechanism is the note structure: debt creates an obligation due in 2033, while the convertible feature can result in equity dilution if holders convert. The company’s revenue growth provides operating context, but does not by itself resolve the cost of the financing or the eventual share impact.
PR Newswire did not disclose the coupon, conversion price, capped-call arrangements, offering expenses or intended use of proceeds in the excerpt. Those terms, along with demand and the final amount issued, remain the material unresolved elements of the transaction.
The next evidence will be the final offering terms and any related filing or closing announcement. The key figures to watch are the coupon, conversion premium, principal amount completed and any stated use of proceeds; no dated event beyond the proposed offering was identified in the announcement.
The proposed $1.05 billion convertible financing leaves HALO with a mixed setup: funding flexibility against future dilution and debt-service risk.
The trade read is mixed because the financing can support Halozyme’s next capital allocation while also creating a future dilution channel and a 2033 debt obligation. The company’s 2025 revenue of $1.4 billion, up 37.6% year over year, gives the transaction an operating-growth backdrop, but the missing coupon, conversion price and use of proceeds prevent a clean directional call.
The setup changes materially if the final coupon, conversion premium, offering size or use of proceeds differs from the proposed terms.
CoverageSource: PR Newswire · Published here WED, SEP 16 · 4:30 PM ET · the only report in this recordHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Halozyme’s $1.4 billion of 2025 revenue and 37.6% year-over-year growth provide a growing operating base for the capital raised.
The proposed $1.05 billion notes add debt due 2033 and could dilute shareholders if the conversion feature is exercised, with no use of proceeds disclosed.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →